FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

研究/GLP-1 Peptide Tirzepatide Shows Promise in Reducing Alcohol Cravings
返回研究图书馆

GLP-1 Peptide Tirzepatide Shows Promise in Reducing Alcohol Cravings

May 25, 2026
Share
新兴研究

基于新兴研究。这些发现很有前景,但需要进一步验证。

关于此分析

本文是基于最近发布的新闻或临床试验公告的人工智能辅助摘要。旨在为肽类研究社区提供快速、易懂的概览。欲获得完整准确性,请参阅下方提供的原始来源。

GLP-1 Peptide Tirzepatide Shows Promise in Reducing Alcohol Cravings

Researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) are exploring a new use for the peptide therapy tirzepatide, commonly used to treat diabetes and obesity. The study aims to determine if this GLP-1 agonist can help individuals with alcohol use disorder (AUD) by reducing their desire to drink.

Background

Alcohol use disorder is a complex condition that affects millions of people worldwide, leading to significant health and social problems. While there are various treatments available, finding new approaches to managing AUD remains a priority for researchers and clinicians alike. GLP-1 agonists like tirzepatide have been shown to help with weight loss and diabetes management, but recent studies suggest they may also play a role in reducing cravings for substances such as alcohol.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is now investigating whether tirzepatide can be used as an adjunct therapy for AUD. This Phase 1 clinical trial focuses on understanding how the brain responds to this peptide drug when given to people with AUD who are not actively seeking treatment. The study involves using [11C]raclopride, a radiotracer that helps visualize dopamine activity in the brain, alongside traditional placebo-controlled methods.

Key Details

The study is recruiting participants aged 21 to 65 years old who have been diagnosed with AUD and are not currently seeking treatment. Participants must also be enrolled in protocol 14-AA-0181 at NIAAA, which provides additional context about their medical history and current health status.

Researchers will monitor how tirzepatide affects the brain's dopaminergic pathways, which are known to play a crucial role in reward-seeking behavior and addiction. By observing changes in dopamine levels using [11C]raclopride PET scans, they hope to gain insights into whether this GLP-1 agonist can help mitigate alcohol cravings.

The trial is still recruiting participants, offering an exciting opportunity for those interested in contributing to the advancement of AUD treatment options through peptide therapy. Understanding how tirzepatide interacts with brain chemistry could pave the way for new therapeutic strategies that leverage the benefits of peptide medications beyond their current applications in diabetes and weight management.

Key Takeaways

  • Peptide Therapy Potential: The study explores whether GLP-1 agonists like tirzepatide can be repurposed to address alcohol use disorder.
  • Neurological Focus: Researchers are using advanced imaging techniques to examine how the drug affects dopamine levels in the brain, providing insights into its mechanisms of action.
  • Patient Inclusion Criteria: The trial is open to individuals aged 21 to 65 with AUD who are not actively seeking treatment and must be enrolled in a specific NIAAA protocol.
  • Clinical Trial Status: This Phase 1 study is currently recruiting participants, marking an early but crucial step in evaluating the potential of tirzepatide for AUD.

What This Means

For the peptide community, this research highlights the versatility and expanding therapeutic scope of GLP-1 agonists. If successful, it could mark a significant shift in how we approach alcohol addiction treatment, potentially offering new hope to those struggling with AUD. The findings may also spur further investigation into other potential applications of these peptides beyond their current indications, underscoring the importance of continued research and regulatory support.

---

Source: ClinicalTrials.gov — Published 6/2023

This article is for informational purposes only and does not constitute medical advice.

编辑注释

此分析使用人工智能工具生成,并由Peptide Contacts编辑团队审核。尽管我们力求准确,但人工智能生成的内容可能包含错误或遗漏。鼓励读者查阅 原始来源 以获取完整细节、方法和数据。

Peptide Contacts提供研究摘要仅供信息参考之用。此内容不构成医疗建议。在做出任何健康决策前,请咨询合格的医疗服务提供者。

Comments

Sign in to join the discussion

本文由人工智能生成,可能存在不准确之处。仅供信息参考之用,并不构成医疗建议。请务必通过原始来源核实信息并在做出任何健康决策前咨询合格的医疗服务提供者。